Intratympanic dexamethasone versus high dosage of betahistine in the treatment of intractable unilateral Meniere disease
| Autor: | Alina Nagy, Felician Chirtes, Luigi Geo Marceanu, Franco Trabalzini, Silviu Albu, Veronica Trombitas, Gregorio Babighian |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Male medicine.medical_specialty Tympanic Membrane Injections Intralesional Placebo Risk Assessment Severity of Illness Index Dexamethasone Drug Administration Schedule law.invention Randomized controlled trial Double-Blind Method law Vertigo Severity of illness otorhinolaryngologic diseases medicine Humans Betahistine Meniere Disease Aged Chi-Square Distribution biology Dose-Response Relationship Drug business.industry Middle Aged biology.organism_classification Surgery Treatment Outcome Otorhinolaryngology Italy Anesthesia Female medicine.symptom business Chi-squared distribution Tinnitus medicine.drug Follow-Up Studies |
| Zdroj: | American journal of otolaryngology. 36(2) |
| ISSN: | 1532-818X |
| Popis: | Purpose The objective of our randomized, double-blind study was to compare the effectiveness of intratympanic (IT) dexamethasone versus high-dosage of betahistine in the treatment of patients with intractable unilateral Meniere disease (MD). Materials and methods Sixty six patients with definite unilateral MD were randomly divided in two groups: Group A received a combination of IT dexamethasone (DX) and identical-appearing placebo pills while Group B received a combination of high-dosage betahistine and IT saline. Intratympanic injections were repeated for three times with an interlude of 3 days. High-dosage of betahistine entailed 144 mg/day. Mean outcome measures consisted of vertigo control, pure tone average (PTA), speech discrimination score, Functional Level Score, Dizziness Handicap Inventory and Tinnitus Handicap Inventory. Results Fifty nine patients completed the study and were available at 12 months for analysis. In Group A complete vertigo control (class A) was attained in 14 patients (46.6%) and substantial control (class B) in 7 patients (20%). In Group B, 12 patients (41%) achieved complete vertigo control (class A), 5 patients (17%) substantial control (class B). There is no statistical difference in vertigo control between the two treatment groups. In Group A hearing was unchanged in 14 patients and improved in 4 patients, while in Group B hearing was unchanged in 16 patients and improved in 2 patients. Conclusions Our preliminary results demonstrate that high-dosage of betahistine achieved similar outcomes as IT dexamethasone in the control of vertigo and hearing preservation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect